A Phase 1 Multicenter, Open-Label Study to Determine the Recommended Dose and Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants with Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose For Each Add On Investigational Component
Categories (click each to see list of all clinical trials associated with that category): Cellular Therapy Support Service - CAR-T (ONC), Myeloma/Plasma Cell Dyscrasia (ONC)
Current Status: Open
Phase: I (Cancer Control)
Principal Investigator: D'Angelo, Christopher
Contact Information:
James Sullivan
jim.sullivan@unmc.edu
Summary